For adults 65 and older, the current best choice is one of the newer pneumococcal conjugate vaccines, either PCV20 (Prevnar 20) or PCV21 (Capvaxive), given as a single shot. In late 2024, the U.S. Advisory Committee on Immunization Practices (ACIP) recommended a single dose of a pneumococcal conjugate vaccine for all adults aged 50 and older who have not previously been vaccinated against pneumococcal disease.1Morbidity and Mortality Weekly Report. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years This marked a shift away from the older 23-valent polysaccharide vaccine (PPSV23) as the go-to option for seniors, and the reasoning involves how aging immune systems respond to different vaccine designs.
How the Two Vaccine Types Differ
Pneumococcal vaccines come in two basic designs, and the distinction matters more the older you get. Polysaccharide vaccines like PPSV23 present pieces of the bacterium’s sugar coating directly to the immune system. This triggers a response that does not involve T cells, one of the immune system’s key memory-building players. The result is a burst of antibodies that fades relatively quickly and does not improve much with repeat doses. Conjugate vaccines, by contrast, chemically link those sugar pieces to a protein carrier. That protein recruits T cells into the process, which helps the immune system form stronger, longer-lasting memory.2PubMed Central. State of pneumococcal vaccine immunity
This distinction becomes especially important in older adults. Aging naturally reduces the variety and effectiveness of antibody-producing B cells, and IgM antibody production drops. The polysaccharide vaccine relies on exactly those pathways that weaken with age, which is why PPSV23 performs noticeably less well in elderly adults than in younger ones.3PubMed Central. Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination Frailty compounds the problem further: in one study, the most frail or aged subjects had the lowest antibody responses after vaccination regardless of serotype.4Vaccine. Immunological responses to pneumococcal vaccine in frail older people The conjugate design partly compensates for these age-related declines by engaging T-cell help, though even conjugate vaccine responses weaken with advancing age. One study found a strong negative correlation between donor age and the strength of the immune response to PCV13.5Nature Immunology. Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults
Which Conjugate Vaccines Are Available
Several pneumococcal conjugate vaccines are now licensed for adults, and they differ mainly in how many serotypes they cover. PCV13, the conjugate vaccine that dominated adult pneumococcal immunization for years, covers 13 bacterial serotypes. PCV15 (Vaxneuvance) covers 15. PCV20 (Prevnar 20) covers 20 serotypes, and PCV21 (Capvaxive) covers 21, though notably a different mix of 21 than you would get by simply adding one serotype to PCV20. PCV21 includes eight serotypes not found in any other licensed pneumococcal vaccine, specifically targeting strains that cause a significant share of disease in adults today.6MMWR. Morbidity and Mortality Weekly Report. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults
Head-to-head immunogenicity comparisons between PCV20 and PCV13 show that for the serotypes they share, PCV20 met noninferiority thresholds, meaning it performed at least as well as PCV13 for those shared strains while also covering additional ones.7PubMed Central. Immunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults PCV21 similarly met noninferiority for serotypes it shares with other vaccines and produced statistically higher responses for most of its unique serotypes.6MMWR. Morbidity and Mortality Weekly Report. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults The practical upshot: both PCV20 and PCV21 represent upgrades over PCV13 for seniors.
What the Landmark Trials Found
The most influential piece of evidence for conjugate vaccine use in older adults comes from the CAPiTA trial, a large randomized controlled trial enrolling nearly 85,000 adults aged 65 and older. PCV13 showed about 46 percent efficacy against first episodes of vaccine-type community-acquired pneumonia, about 45 percent against the non-invasive form, and 75 percent against vaccine-type invasive pneumococcal disease. That protection persisted over an average follow-up of about four years.8PubMed. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults The trial also showed, however, that PCV13 did not reduce pneumonia from all causes combined, only pneumonia caused by the specific serotypes in the vaccine.9PubMed Central. Efficacy and Safety of the Pneumococcal Conjugate-13 Valent Vaccine in Adults
PPSV23, meanwhile, has a more complicated track record. A Japanese case-control study of adults found its effectiveness against invasive pneumococcal disease caused by vaccine serotypes was about 42 percent overall.10PubMed Central. Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013–2017 But other data suggest the benefit drops off sharply with age. In one study, effectiveness against invasive disease in those aged 65 to 74 was roughly 57 percent, while in all patients 65 and older combined, effectiveness was a non-significant 29 percent, and its effect against non-bacteremic pneumonia was even weaker.11Vaccine. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine This pattern reinforces the concern that the polysaccharide vaccine’s reliance on B-cell pathways that decline with age limits its usefulness in the very people who need it most.
For people with diabetes, PPSV23 still appears to provide some protection. A large study of elderly diabetic patients found that vaccination was associated with lower risks of invasive disease, hospitalization, and respiratory failure, along with shorter hospital stays.12PubMed Central. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly The evidence is less encouraging for people with chronic obstructive pulmonary disease (COPD): a Cochrane review found no clear evidence from randomized trials that injectable pneumococcal vaccination significantly reduced illness or death in COPD patients.13Cochrane Database of Systematic Reviews. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease
What the Current U.S. Recommendations Say
As of late 2024, ACIP recommends a single dose of a pneumococcal conjugate vaccine for all adults aged 50 and older who have never received one.1Morbidity and Mortality Weekly Report. Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years The eligible vaccines are PCV20 or PCV21. The old two-step regimen of PCV13 followed by PPSV23, which confused many patients and providers, is no longer the preferred approach. If you already received PCV13 or PCV15 in the past, a single dose of PCV20 can fill in the coverage gap for additional serotypes.
For people with compromised immune systems, the picture requires closer attention. Research following adults on immunosuppressive therapy and adults living with HIV found that good antibody responses persisted in only a minority of these patients three years after initial vaccination. A booster dose of PCV20 five years after priming could trigger recall responses for some serotypes in people whose protection had faded. Importantly, no recall responses were observed for serotypes that were covered only by PPSV23, further supporting the shift toward higher-valent conjugate vaccines over polysaccharide ones.14Clinical Infectious Diseases. Long-term Immunogenicity and Boostability of the 13-valent Pneumococcal Conjugate Vaccine Followed by the 23-valent Pneumococcal Polysaccharide Vaccine in Adults
Ordering Matters If You Receive Multiple Vaccines
Some older adults who began pneumococcal vaccination under previous guidelines received PPSV23 first, then were told they needed a conjugate vaccine. Research suggests this order is less than ideal. Studies comparing immune responses found that giving a conjugate vaccine first, then following with PPSV23 later, produced stronger and broader antibody responses than the reverse sequence.15PubMed Central. Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? Additionally, among those following this sequential approach, waiting a full year between the conjugate dose and the polysaccharide booster produced better results than waiting only six months.16Vaccine. Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years Under current recommendations, though, most seniors will simply receive a single PCV20 or PCV21 dose, which avoids this sequencing problem entirely.
Side Effects Are Mild and Similar Across Vaccines
Seniors tend to worry about vaccine reactions, so it helps to know the side effect profile is reassuring. In the pivotal phase 3 trial for PCV20, the frequency and severity of local and systemic reactions were similar between PCV20 and PCV13 recipients within each age group. Most reactions were mild to moderate, with pain at the injection site being the most common local symptom and muscle pain the most common systemic symptom. Fever occurred in roughly 1 percent of recipients for both vaccines.17Clinical Infectious Diseases. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years PPSV23 has a similar side effect profile. In practical terms, you should not choose between vaccines based on expected side effects, because they are essentially equivalent in that regard.
Getting a pneumococcal vaccine at the same visit as your annual flu shot is both safe and convenient. Studies have found no significant difference in influenza antibody levels whether the flu vaccine was given alone or alongside a pneumococcal vaccine, and no serious adverse events were observed when the two were given simultaneously.18PubMed. Simultaneous influenza and pneumococcal vaccination in elderly individuals 19Vaccine. Reactions after pneumococcal vaccine alone or in combination with influenza vaccine Fall flu-shot season is a natural time to get your pneumococcal vaccine, and combining the visits removes the barrier of scheduling a separate trip.
Why Pneumococcal Disease Hits Older Adults Harder
The urgency behind vaccinating seniors stems from the reality that pneumococcal pneumonia is disproportionately dangerous in this age group. It remains the most common lower respiratory tract infection in older adults, and the consequences are more severe than in younger people due to age-related immune changes and a higher burden of chronic conditions like heart disease, diabetes, and lung disease.20PubMed. Epidemiology of community-acquired pneumonia caused by Streptococcus pneumoniae in older adults: a narrative review Beyond the weakening of antibody responses discussed earlier, aging also alters the physical airways themselves and shifts the composition of the respiratory microbiome, both of which contribute to a decreased ability to fight off pneumococcal bacteria at the initial point of contact.21Frontiers in Cellular and Infection Microbiology. Insights Into the Effects of Mucosal Epithelial and Innate Immune Dysfunction in Older People on Host Interactions With Streptococcus pneumoniae
The Serotype Replacement Problem
One challenge that complicates the “which vaccine is best” question is that pneumococcal bacteria are a moving target. There are more than 90 known serotypes, and when a vaccine successfully suppresses the ones it covers, other serotypes can rise to fill the gap. This phenomenon, called serotype replacement, has been documented repeatedly since the introduction of PCV7, the first conjugate vaccine widely used in children. Among asymptomatic carriers, the prevalence of non-vaccine serotypes increased substantially after PCV7 rollout, resulting in little or no net change in overall bacterial carriage rates.22PubMed Central. Serotype replacement in disease after pneumococcal vaccination
This pattern has continued with later vaccines. Across multiple high-income countries, the proportion of invasive pneumococcal disease caused by non-vaccine serotypes has increased significantly, even in age groups where vaccine-type disease had not yet measurably declined.23Scientific Reports. Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency A clear example comes from New Zealand, where serotype 19A emerged as the dominant strain after it was no longer covered by the national immunization program’s switch to PCV10. By 2022, 19A accounted for about a third of all invasive pneumococcal disease cases across all ages and nearly 60 percent of cases in children under five.24The Lancet Regional Health – Western Pacific. The impact of pneumococcal serotype replacement on the effectiveness of a national immunization program
Serotype replacement is precisely why the vaccine landscape keeps evolving toward higher-valent formulations. PCV20 and PCV21 cast a wider net than PCV13 did, but even they will not cover every circulating serotype. This means the answer to “which vaccine is best” will likely change again within the next decade as surveillance reveals which serotypes are rising and new formulations are developed to match.
Cost-Effectiveness Favors the Conjugate-Only Approach
For health systems and insurers weighing options, economic modeling supports the shift to conjugate vaccines. A cost-effectiveness analysis for U.S. adults found that age-based use of PCV20 alone at age 65 was cost-saving, meaning it both improved health outcomes and reduced overall costs. The older two-dose regimen of PCV15 followed by PPSV23 also improved outcomes but at a dramatically higher cost per quality-adjusted life year gained.25PubMed. Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years and older with underlying conditions For seniors navigating insurance coverage, the single-dose conjugate approach is simpler and more likely to be fully covered under Medicare’s preventive-care benefits.
Disparities in Who Gets Vaccinated
Having a good vaccine matters less if people do not receive it. Pneumococcal vaccination rates among older Americans show significant disparities along racial, economic, and geographic lines. Data from the pre-PCV20 era found that uptake of PCV13 was substantially lower among Black adults (about 36 percent) and Hispanic adults (30 percent) compared to white adults (about 46 percent). Adults in the lowest income bracket had uptake rates roughly half those of the highest-income group, and rural communities lagged behind suburban areas as well.26PubMed Central. Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States Separately, living in an urban area and residing in communities with higher health literacy were both associated with greater likelihood of vaccination.27Vaccine. Pneumococcal vaccination in older adults: An initial analysis of social determinants of health and vaccine uptake The simplification to a single conjugate dose may help close some of these gaps by eliminating the need for a confusing two-visit sequence, but awareness and access remain persistent challenges.
How Recommendations Differ Around the World
If you travel or have family abroad, it is worth knowing that there is no global consensus on pneumococcal vaccination for older adults. Within the European Union alone, vaccine policies vary widely. About a quarter of member states still recommend PPSV23 alone for adults, a similar share use a sequential conjugate-then-polysaccharide strategy, and nearly half now recommend a conjugate vaccine alone, with PCV20 being the most common choice in that group.28PubMed Central. Pneumococcal vaccination offer and schedules in adults in EU countries: An update Some countries like Denmark and Spain use different strategies for different risk groups within their own borders. Outside Europe, age thresholds for routine adult pneumococcal vaccination range from 50 to 70 depending on the country and region.29Vaccine. National recommendations for adult pneumococcal vaccination in countries of the WHO regions of Americas, Africa, Eastern Mediterranean, South East Asia, and Western Pacific The trend globally, though, mirrors the U.S. direction: a move toward higher-valent conjugate vaccines and away from reliance on the polysaccharide vaccine, especially for the elderly. If your country still recommends PPSV23 alone for seniors, it may simply be working with an older guideline that has not yet been updated to reflect the newer vaccine options.